News for Bill.com Holdings, Inc. (BILL)

Bill.com Holdings, Inc. (NYSE:BILL) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. Bill.com Holdings, Inc. (NYSE:BILL) was lowered from an Overweight to Equalweight by Morgan Stanley analysts on June 11. The firm also lowered the company’s price target from $60 to $55. The analysts referenced a reexamination […]

Morgan Stanley has revised its price target for Bill.com Holdings, Inc. (BILL), decreasing it from $100 to $65. Despite this adjustment, the firm maintains an O

Bill.com stock soars to 52-week high, hits $91.33

Fade the rally in this software stock: Wells Fargo

Brian Jacobs, director at BILL Holdings, acquires shares worth over $1.3m

Operator: Good afternoon, and welcome to BILL's Fourth Quarter Fiscal 2024 Earnings Conference Call.

Bill.com beats Q4 expectations, guides Q1 revenue above consensus

Bill.com stock touches 52-week low at $45.9 amid market challenges

The Global B2B Payments Market Size was Valued at USD 71.3 Trillion in 2023 and the Worldwide B2B Payments Market Size is Expected to Reach USD 185.1...

Baird cuts Bill.com shares target on convertible note buyback

BMO downbeat on Bill.com stock, sees stabilization signs

Bill.com Holdings, Inc. misses on earnings expectations. Reported EPS is $0.2861 EPS, expectations were $0.53. Bill.com Holdings, Inc.

Wells Fargo downgrades Bill.com stock over Visa/Mastercard settlement concerns

The advent of the Internet has revolutionized business and created new technologies for people to conduct their daily lives.

Cathie Wood has four decades of investment experience in the finance industry. Her focus as a portfolio manager is solely on publicly traded companies with

The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET)..

Read Analyzing Datable Technology (OTCMKTS:TTMZF) and Bill.com (NYSE:BILL) at ETF Daily News

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.